Global Organ Preservation and Perfusion Solution 麻豆原创 Research Report 2025

Publication ID:

PB502255503

Publication Date:

February 13, 2025

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global market for Organ Preservation and Perfusion Solution was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Organ preservation and perfusion solutions are specialized solutions used to maintain the viability and function of organs during transplantation or storage for medical purposes. These solutions are designed to provide optimal conditions for the preservation and transportation of organs from the donor to the recipient, ensuring minimal damage and maximizing the chances of a successful transplant.
North American market for Organ Preservation and Perfusion Solution is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Organ Preservation and Perfusion Solution is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Organ Preservation and Perfusion Solution in Kidney is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Organ Preservation and Perfusion Solution include 21st Century Medicine, Bridge to Life Limited, BioLife Solutions, Dr. Franz K枚hler Chemie GmbH, XVIVO Perfusion, Artivion, Preservation Solutions, Bristol Myers Squibb, Teva Pharmaceuticals, Lifeline Scientific, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Organ Preservation and Perfusion Solution, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Organ Preservation and Perfusion Solution.
The Organ Preservation and Perfusion Solution market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Organ Preservation and Perfusion Solution market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Organ Preservation and Perfusion Solution companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
21st Century Medicine
Bridge to Life Limited
BioLife Solutions
Dr. Franz K枚hler Chemie GmbH
XVIVO Perfusion
Artivion
Preservation Solutions
Bristol Myers Squibb
Teva Pharmaceuticals
Lifeline Scientific
Advanced Life Solutions
Organ Recovery Systems
Transmedics
Accord Healthcare
Segment by Type
Static Cold Storage (SCS)
Hypothermic Perfusion Preservation (HPP)
Hypothermic Machine Preservation (HMP)
Others
Segment by Application
Kidney
Liver
Heart
Lung
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Organ Preservation and Perfusion Solution company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Organ Preservation and Perfusion Solution 麻豆原创 Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Static Cold Storage (SCS)
1.2.3 Hypothermic Perfusion Preservation (HPP)
1.2.4 Hypothermic Machine Preservation (HMP)
1.2.5 Others
1.3 麻豆原创 by Application
1.3.1 Global Organ Preservation and Perfusion Solution 麻豆原创 Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Kidney
1.3.3 Liver
1.3.4 Heart
1.3.5 Lung
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Organ Preservation and Perfusion Solution 麻豆原创 Perspective (2020-2031)
2.2 Global Organ Preservation and Perfusion Solution Growth Trends by Region
2.2.1 Global Organ Preservation and Perfusion Solution 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
2.2.2 Organ Preservation and Perfusion Solution Historic 麻豆原创 Size by Region (2020-2025)
2.2.3 Organ Preservation and Perfusion Solution Forecasted 麻豆原创 Size by Region (2026-2031)
2.3 Organ Preservation and Perfusion Solution 麻豆原创 Dynamics
2.3.1 Organ Preservation and Perfusion Solution Industry Trends
2.3.2 Organ Preservation and Perfusion Solution 麻豆原创 Drivers
2.3.3 Organ Preservation and Perfusion Solution 麻豆原创 Challenges
2.3.4 Organ Preservation and Perfusion Solution 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Organ Preservation and Perfusion Solution Players by Revenue
3.1.1 Global Top Organ Preservation and Perfusion Solution Players by Revenue (2020-2025)
3.1.2 Global Organ Preservation and Perfusion Solution Revenue 麻豆原创 Share by Players (2020-2025)
3.2 Global Organ Preservation and Perfusion Solution 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Organ Preservation and Perfusion Solution Revenue
3.4 Global Organ Preservation and Perfusion Solution 麻豆原创 Concentration Ratio
3.4.1 Global Organ Preservation and Perfusion Solution 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Organ Preservation and Perfusion Solution Revenue in 2024
3.5 Global Key Players of Organ Preservation and Perfusion Solution Head office and Area Served
3.6 Global Key Players of Organ Preservation and Perfusion Solution, Product and Application
3.7 Global Key Players of Organ Preservation and Perfusion Solution, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Organ Preservation and Perfusion Solution Breakdown Data by Type
4.1 Global Organ Preservation and Perfusion Solution Historic 麻豆原创 Size by Type (2020-2025)
4.2 Global Organ Preservation and Perfusion Solution Forecasted 麻豆原创 Size by Type (2026-2031)
5 Organ Preservation and Perfusion Solution Breakdown Data by Application
5.1 Global Organ Preservation and Perfusion Solution Historic 麻豆原创 Size by Application (2020-2025)
5.2 Global Organ Preservation and Perfusion Solution Forecasted 麻豆原创 Size by Application (2026-2031)
6 North America
6.1 North America Organ Preservation and Perfusion Solution 麻豆原创 Size (2020-2031)
6.2 North America Organ Preservation and Perfusion Solution 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Organ Preservation and Perfusion Solution 麻豆原创 Size by Country (2020-2025)
6.4 North America Organ Preservation and Perfusion Solution 麻豆原创 Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Organ Preservation and Perfusion Solution 麻豆原创 Size (2020-2031)
7.2 Europe Organ Preservation and Perfusion Solution 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Organ Preservation and Perfusion Solution 麻豆原创 Size by Country (2020-2025)
7.4 Europe Organ Preservation and Perfusion Solution 麻豆原创 Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Organ Preservation and Perfusion Solution 麻豆原创 Size (2020-2031)
8.2 Asia-Pacific Organ Preservation and Perfusion Solution 麻豆原创 Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Organ Preservation and Perfusion Solution 麻豆原创 Size by Region (2020-2025)
8.4 Asia-Pacific Organ Preservation and Perfusion Solution 麻豆原创 Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Organ Preservation and Perfusion Solution 麻豆原创 Size (2020-2031)
9.2 Latin America Organ Preservation and Perfusion Solution 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Organ Preservation and Perfusion Solution 麻豆原创 Size by Country (2020-2025)
9.4 Latin America Organ Preservation and Perfusion Solution 麻豆原创 Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Organ Preservation and Perfusion Solution 麻豆原创 Size (2020-2031)
10.2 Middle East & Africa Organ Preservation and Perfusion Solution 麻豆原创 Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Organ Preservation and Perfusion Solution 麻豆原创 Size by Country (2020-2025)
10.4 Middle East & Africa Organ Preservation and Perfusion Solution 麻豆原创 Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 21st Century Medicine
11.1.1 21st Century Medicine Company Details
11.1.2 21st Century Medicine Business Overview
11.1.3 21st Century Medicine Organ Preservation and Perfusion Solution Introduction
11.1.4 21st Century Medicine Revenue in Organ Preservation and Perfusion Solution Business (2020-2025)
11.1.5 21st Century Medicine Recent Development
11.2 Bridge to Life Limited
11.2.1 Bridge to Life Limited Company Details
11.2.2 Bridge to Life Limited Business Overview
11.2.3 Bridge to Life Limited Organ Preservation and Perfusion Solution Introduction
11.2.4 Bridge to Life Limited Revenue in Organ Preservation and Perfusion Solution Business (2020-2025)
11.2.5 Bridge to Life Limited Recent Development
11.3 BioLife Solutions
11.3.1 BioLife Solutions Company Details
11.3.2 BioLife Solutions Business Overview
11.3.3 BioLife Solutions Organ Preservation and Perfusion Solution Introduction
11.3.4 BioLife Solutions Revenue in Organ Preservation and Perfusion Solution Business (2020-2025)
11.3.5 BioLife Solutions Recent Development
11.4 Dr. Franz K枚hler Chemie GmbH
11.4.1 Dr. Franz K枚hler Chemie GmbH Company Details
11.4.2 Dr. Franz K枚hler Chemie GmbH Business Overview
11.4.3 Dr. Franz K枚hler Chemie GmbH Organ Preservation and Perfusion Solution Introduction
11.4.4 Dr. Franz K枚hler Chemie GmbH Revenue in Organ Preservation and Perfusion Solution Business (2020-2025)
11.4.5 Dr. Franz K枚hler Chemie GmbH Recent Development
11.5 XVIVO Perfusion
11.5.1 XVIVO Perfusion Company Details
11.5.2 XVIVO Perfusion Business Overview
11.5.3 XVIVO Perfusion Organ Preservation and Perfusion Solution Introduction
11.5.4 XVIVO Perfusion Revenue in Organ Preservation and Perfusion Solution Business (2020-2025)
11.5.5 XVIVO Perfusion Recent Development
11.6 Artivion
11.6.1 Artivion Company Details
11.6.2 Artivion Business Overview
11.6.3 Artivion Organ Preservation and Perfusion Solution Introduction
11.6.4 Artivion Revenue in Organ Preservation and Perfusion Solution Business (2020-2025)
11.6.5 Artivion Recent Development
11.7 Preservation Solutions
11.7.1 Preservation Solutions Company Details
11.7.2 Preservation Solutions Business Overview
11.7.3 Preservation Solutions Organ Preservation and Perfusion Solution Introduction
11.7.4 Preservation Solutions Revenue in Organ Preservation and Perfusion Solution Business (2020-2025)
11.7.5 Preservation Solutions Recent Development
11.8 Bristol Myers Squibb
11.8.1 Bristol Myers Squibb Company Details
11.8.2 Bristol Myers Squibb Business Overview
11.8.3 Bristol Myers Squibb Organ Preservation and Perfusion Solution Introduction
11.8.4 Bristol Myers Squibb Revenue in Organ Preservation and Perfusion Solution Business (2020-2025)
11.8.5 Bristol Myers Squibb Recent Development
11.9 Teva Pharmaceuticals
11.9.1 Teva Pharmaceuticals Company Details
11.9.2 Teva Pharmaceuticals Business Overview
11.9.3 Teva Pharmaceuticals Organ Preservation and Perfusion Solution Introduction
11.9.4 Teva Pharmaceuticals Revenue in Organ Preservation and Perfusion Solution Business (2020-2025)
11.9.5 Teva Pharmaceuticals Recent Development
11.10 Lifeline Scientific
11.10.1 Lifeline Scientific Company Details
11.10.2 Lifeline Scientific Business Overview
11.10.3 Lifeline Scientific Organ Preservation and Perfusion Solution Introduction
11.10.4 Lifeline Scientific Revenue in Organ Preservation and Perfusion Solution Business (2020-2025)
11.10.5 Lifeline Scientific Recent Development
11.11 Advanced Life Solutions
11.11.1 Advanced Life Solutions Company Details
11.11.2 Advanced Life Solutions Business Overview
11.11.3 Advanced Life Solutions Organ Preservation and Perfusion Solution Introduction
11.11.4 Advanced Life Solutions Revenue in Organ Preservation and Perfusion Solution Business (2020-2025)
11.11.5 Advanced Life Solutions Recent Development
11.12 Organ Recovery Systems
11.12.1 Organ Recovery Systems Company Details
11.12.2 Organ Recovery Systems Business Overview
11.12.3 Organ Recovery Systems Organ Preservation and Perfusion Solution Introduction
11.12.4 Organ Recovery Systems Revenue in Organ Preservation and Perfusion Solution Business (2020-2025)
11.12.5 Organ Recovery Systems Recent Development
11.13 Transmedics
11.13.1 Transmedics Company Details
11.13.2 Transmedics Business Overview
11.13.3 Transmedics Organ Preservation and Perfusion Solution Introduction
11.13.4 Transmedics Revenue in Organ Preservation and Perfusion Solution Business (2020-2025)
11.13.5 Transmedics Recent Development
11.14 Accord Healthcare
11.14.1 Accord Healthcare Company Details
11.14.2 Accord Healthcare Business Overview
11.14.3 Accord Healthcare Organ Preservation and Perfusion Solution Introduction
11.14.4 Accord Healthcare Revenue in Organ Preservation and Perfusion Solution Business (2020-2025)
11.14.5 Accord Healthcare Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 麻豆原创 Size Estimation
13.1.1.3 麻豆原创 Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

Companies Mentioned:

21st Century Medicine
Bridge to Life Limited
BioLife Solutions
Dr. Franz K枚hler Chemie GmbH
XVIVO Perfusion
Artivion
Preservation Solutions
Bristol Myers Squibb
Teva Pharmaceuticals
Lifeline Scientific
Advanced Life Solutions
Organ Recovery Systems
Transmedics
Accord Healthcare

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.